## **PROVIDER OUICK POINTS** PROVIDER INFORMATION



March 9, 2022

## Commercial Pharmacy Benefit Exclusion for Vabysmo<sup>™</sup> and Xipere<sup>™</sup>

Effective **April 1, 2022**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug I	Name
--------	------

Vabysmo<sup>TM</sup> (faricimab-svoa) intravitreal injection for ophthalmic use Xipere<sup>TM</sup> (triamcinolone acetonide) suprachoroidal injection for ophthalmic use

## **Products Impacted**

This applies to commercial lines of business.

## **Questions?**

If you have questions, please contact provider services at (651) 662-5200 or 1-800-262-0820.